{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:32Z","timestamp":1786118852419,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.suc.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:36:28Z","timestamp":1780313788000},"page":"585-602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of Genetics in Gynecologic Malignancies"],"prefix":"10.1016","volume":"106","author":[{"given":"Corbyn M.","family":"Nchako","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara C.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying L.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.suc.2026.03.004_bib1","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/AOG.0000000000003562","article-title":"Hereditary cancer syndromes and risk assessment: ACOG COMMITTEE OPINION, number 793","volume":"134","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.suc.2026.03.004_bib2","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Version 2.2026."},{"issue":"2","key":"10.1016\/j.suc.2026.03.004_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/joim.20106","article-title":"The TP53 tumor suppressor gene: from molecular biology to clinical investigations","volume":"298","author":"Baliakas","year":"2025","journal-title":"J Intern Med"},{"key":"10.1016\/j.suc.2026.03.004_bib4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Sig Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.suc.2026.03.004_bib5","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"A comprehensive review of HER2 in cancer biology and therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.suc.2026.03.004_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.dnarep.2015.11.018","article-title":"Review: clinical aspects of hereditary DNA mismatch repair gene mutations","volume":"38","author":"Sijmons","year":"2016","journal-title":"DNA Repair (Amst)"},{"issue":"10","key":"10.1016\/j.suc.2026.03.004_bib7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41571-025-01054-6","article-title":"Therapeutic targeting of mismatch repair-deficient cancers","volume":"22","author":"Johannet","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.suc.2026.03.004_bib8","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/annonc\/mdw209","article-title":"Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic","volume":"27","author":"Winter","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.suc.2026.03.004_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12885-020-06948-5","article-title":"Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus germline BRCA mutations: a meta-analysis and systematic review","volume":"20","author":"Mohyuddin","year":"2020","journal-title":"BMC Cancer"},{"issue":"6349","key":"10.1016\/j.suc.2026.03.004_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.suc.2026.03.004_bib11","first-page":"1010","article-title":"NCCN clinical practice guidelines in oncology: genetic\/familial high-risk assessment: colorectal, endometrial, gastric. Version 1","volume":"14","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.suc.2026.03.004_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10.1016\/j.suc.2026.03.004_bib13","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.suc.2026.03.004_bib14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.suc.2026.03.004_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ygyno.2024.07.687","article-title":"Incidence of endometrial cancer in BRCA mutation carriers","volume":"189","author":"Kotsopoulos","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.suc.2026.03.004_bib16","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/IGC.0b013e318251cc3f","article-title":"Ovarian cancer screening in the high-risk population--the UK familial ovarian cancer screening study (UKFOCSS)","volume":"22","author":"Rosenthal","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"6 Suppl","key":"10.1016\/j.suc.2026.03.004_bib17","doi-asserted-by":"crossref","first-page":"251S","DOI":"10.1016\/S0197-2456(00)00097-0","article-title":"Prostate, lung, colorectal and ovarian cancer screening trial project team. The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial of the national cancer Institute: history, organization, and status","volume":"21","author":"Gohagan","year":"2000","journal-title":"Control Clin Trials"},{"issue":"9","key":"10.1016\/j.suc.2026.03.004_bib18","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6603725","article-title":"No efficacy of annual gynaecological screening in BRCA1\/2 mutation carriers; an observational follow-up study","volume":"96","author":"Hermsen","year":"2007","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.suc.2026.03.004_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2021.07.034","article-title":"Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system","volume":"163","author":"Na\u00f1ez","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.suc.2026.03.004_bib20","first-page":"411","article-title":"A population-based study of endometrial cancer and familial risk in younger women. Cancer and steroid hormone study group","volume":"5","author":"Gruber","year":"1996","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.suc.2026.03.004_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1127683","article-title":"Updates in gynecologic care for individuals with Lynch syndrome","volume":"13","author":"Underkofler","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.suc.2026.03.004_bib22","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li\u2013Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.1016\/j.suc.2026.03.004_bib23","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/AOG.0000000000002457","article-title":"ACOG committee opinion no. 727: cascade testing: testing women for known hereditary genetic mutations associated with cancer","volume":"131","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.suc.2026.03.004_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"The cancer genome atlas research network. Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.suc.2026.03.004_bib25","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"van den Heerik","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.suc.2026.03.004_bib26","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.suc.2026.03.004_bib27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole\u2013genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.suc.2026.03.004_bib28","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","article-title":"MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10324","key":"10.1016\/j.suc.2026.03.004_bib29","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.suc.2026.03.004_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ijgc-2020-001656","article-title":"Clear cell carcinoma of the ovary: a clinical and molecular perspective","volume":"31","author":"Iida","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.suc.2026.03.004_bib31","doi-asserted-by":"crossref","first-page":"18824","DOI":"10.3390\/ijms140918824","article-title":"ARID1A mutations and PI3K\/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas","volume":"14","author":"Samartzis","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.suc.2026.03.004_bib32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PGP.0b013e318273fd07","article-title":"HNF-1\u03b2 in ovarian carcinomas with serous and clear cell change","volume":"32","author":"DeLair","year":"2013","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10.1016\/j.suc.2026.03.004_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101679","article-title":"Controversies in the management of mucinous ovarian tumors","volume":"35","author":"Blanc-Durand","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.suc.2026.03.004_bib34","first-page":"320","article-title":"Molecular pathways in the development of HPV-induced cervical cancer","volume":"20","author":"Rasi Bonab","year":"2021","journal-title":"EXCLI J"},{"issue":"10","key":"10.1016\/j.suc.2026.03.004_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002666","article-title":"High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study","volume":"15","author":"Lei","year":"2018","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.suc.2026.03.004_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2018.08.013","article-title":"The genetic landscape of 87 ovarian germ cell tumors","volume":"151","author":"Van Nieuwenhuysen","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.suc.2026.03.004_bib37","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/modpathol.2010.145","article-title":"The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary","volume":"23","author":"Jamieson","year":"2010","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.suc.2026.03.004_bib38","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1158\/1078-0432.CCR-21-3394","article-title":"Integrated analysis of ovarian juvenile granulosa cell tumors reveals distinct epigenetic signatures and recurrent TERT rearrangements","volume":"28","author":"Vougiouklakis","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.suc.2026.03.004_bib39","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/PAS.0000000000001232","article-title":"DICER1 and FOXL2 mutation status correlates with clinicopathologic features in ovarian sertoli-leydig cell tumors","volume":"43","author":"Karnezis","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"30","key":"10.1016\/j.suc.2026.03.004_bib40","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.suc.2026.03.004_bib41","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.suc.2026.03.004_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.suc.2026.03.004_bib43","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.suc.2026.03.004_bib44","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.suc.2026.03.004_bib45","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.suc.2026.03.004_bib46","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.suc.2026.03.004_bib47","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.suc.2026.03.004_bib48","article-title":"Risk-reducing bilateral salpingo oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"8","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.suc.2026.03.004_bib49","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2021.1590","article-title":"Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1\/2 pathogenic variant carriers: a nonrandomized controlled trial","volume":"7","author":"Steenbeek","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.suc.2026.03.004_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2019.04.055","article-title":"WISP: a prospective, multi-center trial of salpingectomy with delayed oophorectomy versus risk reducing salpingo-oophorectomy in women at increased risk for hereditary ovarian cancer","volume":"154","author":"Lu","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.suc.2026.03.004_bib51","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jama.296.12.1507","article-title":"Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review","volume":"296","author":"Lindor","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.suc.2026.03.004_bib52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41436-020-01029-1","article-title":"Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report","volume":"23","author":"Dominguez-Valentin","year":"2021","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.suc.2026.03.004_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2025.101557","article-title":"Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Ngeow","year":"2025","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.suc.2026.03.004_bib54","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/AOG.0000000000003729","article-title":"Clinical effects of early or surgical menopause","volume":"135","author":"Kingsberg","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.suc.2026.03.004_bib55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ygyno.2024.10.007","article-title":"What happens after menopause? (WHAM): a prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO)","volume":"191","author":"Hickey","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"25","key":"10.1016\/j.suc.2026.03.004_bib56","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American heart association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.suc.2026.03.004_bib57","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaoncol.2017.4942","article-title":"Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers","volume":"4","author":"Michels","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.suc.2026.03.004_bib58","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2019.06.017","article-title":"Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: society of gynecologic oncology and American Society for reproductive medicine evidence-based review","volume":"155","author":"Chen","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.suc.2026.03.004_bib59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.2015.6789","article-title":"Female hormonal factors and the risk of endometrial cancer in Lynch syndrome","volume":"314","author":"Dashti","year":"2015","journal-title":"JAMA"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610926000320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610926000320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:57:30Z","timestamp":1786035450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610926000320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0039610926000320"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2026.03.004","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Genetics in Gynecologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}